ABCL
Neutral signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
AbCellera Biologics Inc.
- Nom
- AbCellera Biologics Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $3.8B
- Employés
- 562
- PDG
- Carl Hansen
- Site web
- https://www.abcellera.com
- Marché
- ABSIDNAGENB
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 37200 titres (~383904 USD)
- Insiders
- Booth Andrew
- Total bought
-
$383,904
Avg buy (VWAP, 90d window) $10.47 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-14
- Last synced
-
2026-08-15 10:30:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-18 | Montalbano John S. | Buy · P | 10,000 | $11.03 | $110,300 | Form 4 |
| 2026-08-14 | Booth Andrew | Buy · P | 37,200 | $10.32 | $383,904 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
ABCL presents a deeply conflicted setup: while the Phase 2 ABCL635 catalyst and insider buy provide a moderate event-driven signal, the company's severe operational distress — negative margins, extreme cash burn, and a…
The first sentence of the analysis written for ABCL on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 11.32 · operating margin -289% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.6% | 100.0% | 100.0% | 86.3% | 87.9% | |
| Ebit Margin | -236.4% | -1044.4% | -586.6% | 46.8% | 59.1% | |
| Ebitda Margin | -198.0% | -708.0% | -505.3% | 53.6% | 63.7% | |
| Operating Profit Margin | -289.0% | -1091.7% | -623.8% | 44.6% | 54.5% | |
| Pretax Profit Margin | -236.4% | -695.0% | -457.7% | 49.3% | 58.4% | |
| Continuous Operations Profit Margin | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | |
| Net Profit Margin | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | |
| Bottom Line Profit Margin | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | |
| Current Ratio | 11.324 | 9.807 | 7.327 | 8.667 | 7.705 | |
| Quick Ratio | 11.226 | 9.807 | 7.318 | 8.654 | 7.691 | |
| Solvency Ratio | -0.301 | -0.216 | -0.344 | 0.623 | 0.583 | |
| Cash Ratio | 1.998 | 2.040 | 1.120 | 3.267 | 3.946 | |
| Price To Earnings Ratio | -6.980 | -5.327 | -11.196 | 18.089 | 25.536 | |
| Price To Earnings Growth Ratio | 0.640 | -0.679 | 0.059 | 0.000 | 0.340 | |
| Forward Price To Earnings Growth Ratio | 0.640 | -0.679 | 0.059 | 0.000 | 0.340 | |
| Price To Earnings Diluted Ratio | -6.980 | -5.327 | -11.196 | 20.260 | 29.792 | |
| Price To Earnings Diluted Growth Ratio | 0.640 | -0.679 | 0.055 | 4.862 | 4.469 | |
| Price To Book Ratio | 1.057 | 0.817 | 1.433 | 2.341 | 3.844 | |
| Price To Sales Ratio | 13.598 | 29.909 | 43.423 | 5.949 | 10.510 | |
| Price To Free Cash Flow Ratio | -5.869 | -4.613 | -13.603 | 14.107 | 21.186 | |
| Price To Operating Cash Flow Ratio | -7.781 | -7.944 | -37.631 | 10.411 | 16.123 | |
| Debt To Assets Ratio | 0.106 | 0.048 | 0.052 | 0.053 | 0.030 | |
| Debt To Equity Ratio | 0.148 | 0.062 | 0.067 | 0.067 | 0.039 | |
| Debt To Capital Ratio | 0.129 | 0.058 | 0.063 | 0.063 | 0.038 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.403 | 1.288 | 1.291 | 1.249 | 1.285 | |
| Working Capital Turnover Ratio | 0.112 | 0.040 | 0.046 | 0.566 | 0.494 | |
| Operating Cash Flow Ratio | -2.042 | -1.417 | -0.369 | 2.344 | 2.027 | |
| Operating Cash Flow Sales Ratio | -1.748 | -3.765 | -1.154 | 0.571 | 0.652 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.326 | 1.722 | 2.766 | 0.738 | 0.761 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 44.397 | 33.199 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 53.526 | 39.122 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.917 | -1.661 | -0.567 | 3.372 | 6.105 | |
| Capital Expenditure Coverage Ratio | -3.070 | -1.385 | -0.566 | 3.817 | 4.184 | |
| Dividend Paid And Capex Coverage Ratio | -3.070 | -1.385 | -0.566 | 3.817 | 4.184 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.965 | -3.779 | -8.302 | 9.930 | 14.666 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.6% | ▼-38.4% | ▼-25.5% |
| Ebit Margin | -236.4% | ▲808.1% | ▲115.9% |
| Ebitda Margin | -198.0% | ▲510.0% | ▲60.8% |
| Operating Profit Margin | -289.0% | ▲802.7% | ▲92.1% |
| Pretax Profit Margin | -236.4% | ▲458.6% | ▲19.9% |
| Continuous Operations Profit Margin | -194.9% | ▲369.9% | ▲19.4% |
| Net Profit Margin | -194.9% | ▲369.9% | ▲19.4% |
| Bottom Line Profit Margin | -194.9% | ▲369.9% | ▲19.4% |
| Current Ratio | 11.324 | ▲1.517 | ▲2.358 |
| Quick Ratio | 11.226 | ▲1.418 | ▲2.287 |
| Solvency Ratio | -0.301 | ▼-0.085 | ▼-0.370 |
| Cash Ratio | 1.998 | ▼-0.042 | ▼-0.476 |
| Price To Earnings Ratio | -6.980 | ▼-1.652 | ▼-11.004 |
| Price To Earnings Growth Ratio | 0.640 | ▲1.319 | ▲0.568 |
| Forward Price To Earnings Growth Ratio | 0.640 | ▲1.319 | ▲0.568 |
| Price To Earnings Diluted Ratio | -6.980 | ▼-1.652 | ▼-12.289 |
| Price To Earnings Diluted Growth Ratio | 0.640 | ▲1.319 | ▼-1.230 |
| Price To Book Ratio | 1.056 | ▲0.240 | ▼-0.842 |
| Price To Sales Ratio | 13.598 | ▼-16.312 | ▼-7.080 |
| Price To Free Cash Flow Ratio | -5.869 | ▼-1.256 | ▼-8.111 |
| Price To Operating Cash Flow Ratio | -7.781 | ▲0.163 | ▼-2.416 |
| Debt To Assets Ratio | 0.105 | ▲0.058 | ▲0.048 |
| Debt To Equity Ratio | 0.148 | ▲0.086 | ▲0.071 |
| Debt To Capital Ratio | 0.129 | ▲0.071 | ▲0.059 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.403 | ▲0.115 | ▲0.100 |
| Working Capital Turnover Ratio | 0.112 | ▲0.072 | ▼-0.139 |
| Operating Cash Flow Ratio | -2.042 | ▼-0.625 | ▼-2.150 |
| Operating Cash Flow Sales Ratio | -1.748 | ▲2.017 | ▼-0.659 |
| Free Cash Flow Operating Cash Flow Ratio | 1.326 | ▼-0.396 | ▼-0.137 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▼-15.519 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▼-18.529 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.917 | ▲0.744 | ▼-2.183 |
| Capital Expenditure Coverage Ratio | -3.070 | ▼-1.685 | ▼-3.666 |
| Dividend Paid And Capex Coverage Ratio | -3.070 | ▼-1.685 | ▼-3.666 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.965 | ▼-3.187 | ▼-8.075 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.02B | $862.4M | $1.65B | $2.89B | $3.94B | |
| Enterprise value | $1.04B | $771.4M | $1.60B | $2.58B | $3.51B | |
| EV / Sales | 13.79x | 26.75x | 41.95x | 5.32x | 9.35x | |
| EV / Op. cash flow | -7.89x | -7.11x | -36.36x | 9.31x | 14.34x | |
| EV / Free cash flow | -5.95x | -4.13x | -13.14x | 12.62x | 18.84x | |
| EV / EBITDA | -6.96x | -3.78x | -8.30x | 9.93x | 14.67x | |
| Net debt / EBITDA | -0.10x | 0.45x | 0.29x | -1.17x | -1.82x | |
| Current ratio | 11.32x | 9.81x | 7.33x | 8.67x | 7.71x | |
| Income quality | 0.90x | 0.67x | 0.30x | 1.75x | 1.59x | |
| Graham number | — | — | — | $7 | $7 | |
| Graham net-net | $1 | $1 | $2 | $2 | $2 | |
| Tax burden | 82.4% | 81.3% | 84.1% | 66.3% | 70.0% | |
| Interest burden | 100.0% | 66.5% | 78.0% | 105.3% | 98.8% | |
| Working capital | $663.9M | $674.8M | $753.0M | $907.2M | $809.1M | |
| Invested capital | $1.18B | $1.11B | $1.21B | $1.30B | $1.12B | |
| Return on assets | -10.8% | -12.0% | -9.8% | 10.3% | 11.6% | |
| Operating ROA | -16.0% | -22.1% | -15.7% | 15.1% | 17.6% | |
| Return on tangible assets | -11.5% | -12.8% | -11.1% | 11.6% | 13.7% | |
| Return on equity | -15.1% | -15.4% | -12.7% | 12.9% | 15.0% | |
| Return on invested capital | -13.8% | -19.9% | -14.5% | 10.1% | 11.9% | |
| Return on capital employed | -16.8% | -24.5% | -17.3% | 15.2% | 17.1% | |
| Earnings yield | -14.3% | -18.9% | -8.9% | 5.5% | 3.9% | |
| Free cash flow yield | -17.0% | -21.7% | -7.4% | 7.1% | 4.7% | |
| Capex / Op. cash flow | -32.6% | -72.2% | -176.6% | 26.2% | 23.9% | |
| Capex / Depreciation | 192.9% | 80.8% | 250.9% | 219.5% | 338.9% | |
| Capex / Sales | 56.9% | 271.9% | 203.8% | 15.0% | 15.6% | |
| SG&A / Sales | 101.9% | 296.5% | 197.7% | 13.8% | 13.0% | |
| R&D / Sales | 248.7% | 580.1% | 462.0% | 22.2% | 16.5% | |
| Stock comp / Sales | 74.3% | 234.4% | 168.8% | 10.2% | 8.2% | |
| Intangibles / Total assets | 6.4% | 6.6% | 11.3% | 11.6% | 14.9% | |
| Days sales outstanding | 745d | 1166d | 618d | 78d | 170d | |
| Days payables outstanding | 319d | 0d | 0d | 81d | 120d | |
| Operating cycle | 826d | 1166d | 618d | 86d | 184d | |
| Cash conversion cycle | 506d | 1166d | 618d | 5d | 64d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-13 AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
- 2026-08-12 What''s Going on With AbCellera Biologics Stock On Wednesday? AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at alleviating menopausal hot flashes.
- 2026-08-11 AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
- 2026-08-11 Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL) AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) was the target of unusually large options trading on Monday. Stock investors purchased 16,666 call options on the company. This is an increase of approximately 151% compared to the typical daily volume of 6,636 call options. AbCellera Biologics News Roundup Here are the key news stories impacting
- 2026-08-10 AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
- 2026-08-10 AbCellera Biologics Menopause Drug Data Shows ''New Efficacy Benchmark'' AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.
- 2026-08-10 AbCellera Stock Jumps 33% on a Positive Menopause Trial AbCellera (ABCL), a Vancouver clinical-stage antibody biotech, rose 33.19% intraday after its experimental menopause drug ABCL635 met both primary goals in a Ph
- 2026-08-10 AbCellera''s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.
- 2026-08-10 AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi [url="]AbCellera[/url] (Nasdaq: ABCL) today announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an
- 2026-08-10 AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise AbCellera said Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up 24% in premarket trading.